$14.06
0.48% today
Nasdaq, Apr 01, 06:16 pm CET
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Inhibrx Inc Stock price

$13.99
+0.74 5.58% 1M
-1.67 10.66% 6M
-1.41 9.16% YTD
-16.83 54.60% 1Y
-5.70 28.95% 3Y
-4.24 23.27% 5Y
-4.24 23.27% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.13 0.92%
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Key metrics

Market capitalization $202.52m
Enterprise Value $57.97m
P/E (TTM) P/E ratio 0.12
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 289.85
P/S ratio (TTM) P/S ratio 1,012.60
P/B ratio (TTM) P/B ratio 1.52
Revenue (TTM) Revenue $200.00k
EBIT (operating result TTM) EBIT $-331.45m
Free Cash Flow (TTM) Free Cash Flow $-197.01m
Cash position $152.60m
EPS (TTM) EPS $116.58
P/E forward negative
Short interest 5.71%
Show more

Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Inhibrx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Inhibrx Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Inhibrx Inc forecast:

Hold
100%

Financial data from Inhibrx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.20 0.20
89% 89%
100%
- Direct Costs 2.28 2.28
11% 11%
1,140%
-2.08 -2.08
700% 700%
-1,040%
- Selling and Administrative Expenses 125 125
377% 377%
62,610%
- Research and Development Expense 202 202
6% 6%
100,930%
-329 -329
52% 52%
-164,580%
- Depreciation and Amortization 2.28 2.28
11% 11%
1,140%
EBIT (Operating Income) EBIT -331 -331
51% 51%
-165,724%
Net Profit 1,688 1,688
799% 799%
843,785%

In millions USD.

Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibrx Inc Stock News

Neutral
PRNewsWire
15 days ago
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Neutral
PRNewsWire
2 months ago
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, ...
Neutral
PRNewsWire
3 months ago
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders ...
More Inhibrx Inc News

Company Profile

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Head office United States
CEO Mark Lappe
Employees 161
Founded 2010
Website www.inhibrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today